Genflow Biosciences PLC WQ5
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €0.04
- Day Range
- €0.04–0.04
- 52-Week Range
- €0.01–0.17
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €13.99 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Genflow Biosciences PLC is a preclinical biotechnology company focused on developing innovative biological interventions aimed at tackling the effects of aging, potentially slowing or halting the aging process and reducing the incidence of age-related diseases and thereby increasing life span. The company is also focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with age.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.genflowbio.com
Valuation
|
Metric
|
WQ5
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 13.98 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
WQ5
|
|---|---|
Quick Ratio | 2.97 |
Current Ratio | 3.09 |
Interest Coverage | — |
Quick Ratio
WQ5
Profitability
|
Metric
|
WQ5
|
|---|---|
Return on Assets (Normalized) | −87.23% |
Return on Equity (Normalized) | −101.57% |
Return on Invested Capital (Normalized) | −101.57% |
Return on Assets
WQ5
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Rtthgks | Ywxwz | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Tqvtxnvb | Bswytmb | $114.2 Bil | |||
| Moderna Inc
MRNA
| Pwnbpyry | Qqd | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Kmypztx | Pxs | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Rnstldmp | Lws | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Fcxwxjxyk | Bqjsbb | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Jvqkwkg | Jqtchqt | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Vcrjjqgt | Pyy | $12.8 Bil | |||
| Incyte Corp
INCY
| Kctsjmc | Fmrzyj | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Gfqcqkqwt | Yhhnt | $12.2 Bil |